Mathematical modeling provides kinetic details of the human immune response to vaccination

Frontiers in Cellular and Infection Microbiology

Volumn 4, Issue DEC, 2014, Pages

  Le, Dustin ^a   Miller, Joseph D ^b   Ganusov, Vitaly V ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA VACCINE; YELLOW FEVER VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; LYMPHOCYTE PROLIFERATION; MATHEMATICAL MODEL; NONHUMAN; NORMAL HUMAN; PLASMA CELL; SMALLPOX; T LYMPHOCYTE; VACCINATION; VIRAL CLEARANCE; VIRUS INFECTION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; YOUNG ADULT;

EID: 84991011547     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2014.00177     Document Type: Article

References (80)

1. Altman, J., Moss, P., Goulder, P., Barouch, D., McHeyzer-Williams, M., Bell, J., McMichael, A. & Davis, M. 1996 Phenotypic analysis of antigen-specific T lymphocytes. Science, 274(5284), 94-6.
2. Murali-Krishna, K., Altman, J., Suresh, M., Sourdive, D., Zajac, A., Miller, J., Slansky, J. & Ahmed, R. 1998 Counting antigen-specific CD8+ T cells: A re-evaluation of bystander activation during viral infection. Immunity, 8, 177-187.
3. Su, L. F. & Davis, M. M. 2013 Antiviral memory phenotype T cells in unexposed adults. Immunol Rev, 255(1), 95-109. doi:10.1111/imr.12095.
4. Reinhardt, R., Khoruts, A., Merica, R., Zell, T. & Jenkins, M. 2001 Visualizing the generation of memory CD4 T cells in the whole body. Nature, 410(6824), 101-5.
5. Moon, J., Chu, H., Pepper, M., McSorley, S., Jameson, S., Kedl, R. & Jenkins, M. 2007 Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity, 27(2), 203-13.
6. Obar, J. J., Khanna, K. M. & Lefrancois, L. 2008 Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity, 28(6), 859-69.
7. Gruta, N. L. L., Rothwell, W. T., Cukalac, T., Swan, N. G., Valkenburg, S. A., Kedzierska, K., Thomas, P. G., Doherty, P. C. & Turner, S. J. 2010 Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J Clin Invest, 120(6), 1885-1894. doi:10.1172/JCI41538.
8. Jenkins, M. K. & Moon, J. J. 2012 The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol, 188(9), 4135-4140. doi: 10.4049/jimmunol.1102661.
9. Alanio, C., Lemaitre, F., Law, H. K., Hasan, M. & Albert, M. L. 2010 Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood, 115(18), 3718-25.
10. Murali-Krishna, K., Lau, L. L., Sambhara, S., Lemonnier, F., Altman, J. & Ahmed, R. 1999 Persistence of memory CD8 T cells in MHC class I-deficient mice. Science, 286(5443), 1377-81.
11. Antia, R., Ganusov, V. V. & Ahmed, R. 2005 The role of models in understanding CD8+ T-cell memory. Nat Rev Immunol, 5(2), 101-111.
12. Homann, D., Teyton, L. & Oldstone, M. B. 2001 Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med, 7(8), 913-919. doi:10.1038/90950.
13. Kotturi, M. F., Scott, I., Wolfe, T., Peters, B., Sidney, J., Cheroutre, H., von Herrath, M. G., Buchmeier, M. J., Grey, H. et al. 2008 Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol, 181(3), 2124-33.
14. La Gruta, N. L., Rothwell, W. T., Cukalac, T., Swan, N. G., Valkenburg, S. A., Kedzierska, K., Thomas, P. G., Doherty, P. C. & Turner, S. J. 2010 Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J Clin Invest, 120(6), 1885-94.
15. Chen, W. S., Anton, L. C., Bennink, J. R. & Yewdell, J. W. 2000 Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity, 12(1), 83-93.
16. De Boer, R. J., Oprea, M., Antia, R., Murali-Krishna, K., Ahmed, R. & Perelson, A. S. 2001 Recruitment times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic choriomeningitis virus. Journal of Virology, 75(22), 10 663-10 669.
17. De Boer, R. J., Homann, D. & Perelson, A. S. 2003 Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol, 171(8), 3928-35.
18. Althaus, C. L., Ganusov, V. V. & De Boer, R. J. 2007 Dynamics of CD8+ T cell responses during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol, 179(5), 2944-2951.
19. Slifka, M., Antia, R., Whitmire, J. & Ahmed, R. 1998 Humoral immunity due to long-lived plasma cells. Immunity, 8(3), 363-72.
20. Anderson, S. M., Khalil, A., Uduman, M., Hershberg, U., Louzoun, Y., Haberman, A. M., Kleinstein, S. H. & Shlomchik, M. J. 2009 Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to lowaffinity cells. J Immunol, 183(11), 7314-7325. doi:10.4049/jimmunol.0902452.
21. Carrat, F., Vergu, E., Ferguson, N. M., Lemaitre, M., Cauchemez, S., Leach, S. & Valleron, A.-J. 2008 Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol, 167(7), 775-785. doi:10.1093/aje/kwm375.
22. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. 2010 The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol, 10(1), 11-23.
23. Perreau, M., Levy, Y. & Pantaleo, G. 2013 Immune response to HIV. Curr Opin HIV AIDS, 8(4), 333-340. doi:10.1097/COH.0b013e328361faf4.
24. Park, S.-H. & Rehermann, B. 2014 Immune responses to HCV and other hepatitis viruses. Immunity, 40(1), 13-24. doi:10.1016/j.immuni.2013.12.010.
25. Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S. et al. 2008 Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity, 28(5), 710-22.
26. Ahmed, R. & Akondy, R. S. 2011 Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol, 89(3), 340-345. doi:10.1038/icb.2010.155.
27. Cottin, P., Niedrig, M. & Domingo, C. 2013 Safety profile of the yellow fever vaccine Stamaril: a 17-year review. Expert Rev Vaccines, 12(11), 1351-1368. doi:10.1586/14760584.2013.836320.
28. Gotuzzo, E., Yactayo, S. & Cordova, E. 2013 Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg, 89(3), 434-444. doi:10.4269/ajtmh.13-0264.
29. Hammarlund, E., Lewis, M., Hansen, S., Strelow, L., Nelson, J., Sexton, G., Hanifin, J. & Slifka, M. 2003 Duration of antiviral immunity after smallpox vaccination. Nat Med, 9(9), 1131-7.
30. Amanna, I. J., Carlson, N. E. & Slifka, M. K. 2007 Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med, 357(19), 1903-1915. doi:10.1056/NEJMoa066092.
31. Amanna, I. J., Messaoudi, I. & Slifka, M. K. 2008 Protective immunity following vaccination: how is it defined? Hum Vaccin, 4(4), 316-319.
32. Akondy, R. S., Monson, N. D., Miller, J. D., Edupuganti, S., Teuwen, D., Wu, H., Quyyumi, F., Garg, S., Altman, J. D. et al. 2009 The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol, 183(12), 7919-30.
33. Newman, F. K., Frey, S. E., Blevins, T. P., Mandava, M., Bonifacio, A., Yan, L. & Belshe, R. B. 2003 Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol, 41(7), 3154-3157.
34. Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L. et al. 2008 Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 453(7195), 667-671.
35. Riou, C., Ganusov, V. V., Campion, S., Mlotshwa, M., Liu, M. K. P., Whale, V. E., Goonetilleke, N., Borrow, P., Ferrari, G. et al. 2012 Distinct kinetics of Gag-specific CD4(+) and CD8(+) T cell responses during acute HIV-1 infection. J Immunol, 188(5), 2198-2206. doi:10.4049/jimmunol.1102813.
36. Ganusov, V. V. & Auerbach, J. 2014 Mathematical modeling reveals kinetics of lymphocyte recirculation in the whole organism. PLoS Comp Biol, 10, e1003 586.
37. Trepel, F. 1974 Number and distribution of lymphocytes in man. A critical analysis. Klin. Wschr., 52, 511-515.
38. Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L., Mittler, J. E., Markowitz, M., Moore, J. P., Perelson, A. S. et al. 1999 Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet, 354(9192), 1782-1785.
39. Guedj, J., Dahari, H., Rong, L., Sansone, N. D., Nettles, R. E., Cotler, S. J., Layden, T. J., Uprichard, S. L. & Perelson, A. S. 2013 Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A, 110(10), 3991-3996. doi:10.1073/pnas.1203110110.
40. Perelson, A. S. 2002 Modelling viral and immune system dynamics. Nature Rev Immunol, 2(1), 28-36.
41. Goldsby, R. A., Kindt, T. J. & Osborne, B. 2007 Kuby Immunology, 6th edition. W. H. Freeman.
42. Burnham, K. P. & Anderson, D. R. 2002 Model selection and multimodel inference: a practical information-theoretic approach. Springer-Verlag, New York.
43. Bates, D. M. & Watts, D. G. 1988 Nonlinear regression analysis and its applications. John Wiles & Sons, Inc.
44. Blattman, J. N., Antia, R., Sourdive, D. J.,Wang, X., Kaech, S. M., Murali-Krishna, K., Altman, J. D. & Ahmed, R. 2002 Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med, 195(5), 657-664.
45. Stemberger, C., Huster, K. M., Koffler, M., Anderl, F., Schiemann, M., Wagner, H. & Busch, D. H. 2007 A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity, 27(6), 985-997. doi:10.1016/j.immuni.2007.10.012.
46. Lau, L., Jamieson, B., Somasundaram, T. & Ahmed, R. 1994 Cytotoxic T-cell memory without antigen. Nature, 369, 648-652.
47. Doherty, P. C. & Christensen, J. P. 2000 Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol, 18, 561-592.
48. De Boer, R. J. & Perelson, A. S. 1998 Target cell limited and immune control models of HIV infection: a comparison. J Theor Biol, 190(3), 201-14.
49. Ganusov, V. V., Barber, D. L. & De Boer, R. J. 2011 Killing of targets by CD8 T cells in the mouse spleen follows the law of mass action. PLoS One, 6(1), e15 959.
50. Ganusov, V. V. & De Boer, R. J. 2008 Estimating in vivo death rates of targets due to CD8 T-cell-mediated killing. J Virol, 82(23), 11 749-11 757.
51. Graw, F. & Regoes, R. R. 2009 Investigating CTL mediated killing with a 3D cellular automaton. PLoS Comput Biol, 5(8), e1000 466.
52. Gadhamsetty, S., Maree, A. F. M., Beltman, J. B. & de Boer, R. J. 2014 A general functional response of cytotoxic T lymphocyte-mediated killing of target cells. Biophys J, 106(8), 1780-1791. doi:10.1016/j.bpj.2014.01.048.
53. Jerne, N. K. & Nordin, A. A. 1963 Plaque Formation in Agar by Single Antibody-Producing Cells. Science, 140(3565), 405. doi:10.1126/science.140.3565.405.
54. Jerne, N. K., Henry, C., Nordin, A. A., Fuji, H., Koros, A. M. & Lefkovits, I. 1974 Plaque forming cells: methodology and theory. Transplant Rev, 18, 130-191.
55. Turesson, I. 1976 Distribution of immunoglobulin-containing cells in human bone marrow and lymphoid tissues. Acta Med Scand, 199(4), 293-304.
56. Kaech, S. M. & Cui, W. 2012 Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol, 12(11), 749-61.
57. Mbow, M. L., Rutti, B. & Brossard, M. 1994 Infiltration of CD4+ CD8+ T cells, and expression of ICAM-1, Ia antigens, IL-1 alpha and TNF-alpha in the skin lesion of BALB/c mice undergoing repeated infestations with nymphal Ixodes ricinus ticks. Immunology, 82(4), 596-602.
58. Co, M. D., Terajima, M., Cruz, J., Ennis, F. A. & Rothman, A. L. 2002 Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLAB35- restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology, 293(1), 151-63.
59. Santos, A. P., Matos, D. C., Bertho, A. L., Mendonca, S. C. & Marcovistz, R. 2008 Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine, 42(2), 152-5.
60. Davenport, M., Ribeiro, R. & Perelson, A. 2004 Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol, 78(18), 10 096-103.
61. Demetrius, L. 2005 Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep, 6 Spec No, S39-S44. doi: 10.1038/sj.embor.7400422.
62. Gerna, G. 2012 Endothelial cells and CMV dissemination. Future Microbiol, 7(4), 441-444. doi:10.2217/fmb.12.12.
63. Slifka, M. K. 2014 Vaccine-Mediated Immunity Against Dengue and the Potential for Long- Term Protection Against Disease. Front Immunol, 5, 195. doi:10.3389/fimmu.2014.00195.
64. Guirakhoo, F., Kitchener, S., Morrison, D., Forrat, R., McCarthy, K., Nichols, R., Yoksan, S., Duan, X., Ermak, T. H. et al. 2006 Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin, 2(2), 60-67.
65. Hansen, S. G., Piatak, M., Ventura, A. B., Hughes, C. M., Gilbride, R. M., Ford, J. C., Oswald, K., Shoemaker, R., Li, Y. et al. 2013 Immune clearance of highly pathogenic SIV infection. Nature, 502(7469), 100-104. doi:10.1038/nature12519.
66. Slifka, M. K. & Amanna, I. 2014 How advances in immunology provide insight into improving vaccine efficacy. Vaccine, 32(25), 2948-2957. doi:10.1016/j.vaccine.2014.03.078.
67. Shaulov, A. & Murali-Krishna, K. 2008 CD8 T cell expansion and memory differentiation are facilitated by simultaneous and sustained exposure to antigenic and inflammatory milieu. J Immunol, 180(2), 1131-1138.
68. Kaech, S. M. & Ahmed, R. 2001 Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol, 2(5), 415-422.
69. Nossal, G. J. & Makela, O. 1962 Elaboration of antibodies by single cells. Annu Rev Microbiol, 16, 53-74. doi:10.1146/annurev.mi.16.100162.000413.
70. Salmon, S. E. & Smith, B. A. 1970 Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest, 49(6), 1114-1121.
71. Hiramoto, R. N., McGhee, J. R. & Hamlin, N. M. 1972 Measurement of antibody release from single cells. I. J Immunol, 109(5), 961-967.
72. Hiramoto, R. N., Hamlin, N. M. & McGhee, J. R. 1972 Measurement of antibody release from single cells. II. J Immunol, 109(5), 968-973.
73. Conrad, R. E. & Ingraham, J. S. 1974 Rate of hemolytic antibody production by single cells in vivo in rabbits. J Immunol, 112(1), 17-25.
74. Hibi, T. & Dosch, H. M. 1986 Limiting dilution analysis of the B cell compartment in human bone marrow. Eur J Immunol, 16(2), 139-145. doi:10.1002/eji.1830160206.
75. Bromage, E., Stephens, R. & Hassoun, L. 2009 The third dimension of ELISPOTs: quantifying antibody secretion from individual plasma cells. J Immunol Methods, 346(1-2), 75-79.
76. Vieira, P. & Rajewsky, K. 1986 The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half-life of 6-8 days. Eur J Immunol, 16(7), 871-874. doi:10.1002/eji.1830160727.
77. Vieira, P. & Rajewsky, K. 1988 The half-lives of serum immunoglobulins in adult mice. Eur J Immunol, 18(2), 313-316. doi:10.1002/eji.1830180221.
78. Alyanakian, M.-A., Bernatowska, E., Scherrmann, J.-M., Aucouturier, P. & Poplavsky, J.-L. 2003 Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang, 84(3), 188-192.
79. Salfeld, J. G. 2007 Isotype selection in antibody engineering. Nat Biotechnol, 25(12), 1369-1372. doi:10.1038/nbt1207-1369.
80. Pegu, A., Yong Yang, Z., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W. et al. 2014 Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med, 6(243), 243ra88.